How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?
ConclusionSerum lipid levels changed variously in EOC patients receiving bevacizumab treatment. A prediction model for PFS of EOC patients receiving bevacizumab treatment was constructed, and it can be beneficial in determining the prognosis, selecting a treatment plan, and monitoring these patients’ long-term care.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Avastin | Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Cholesterol | Epithelial Cancer | Learning | Ovarian Cancer | Ovaries | Statistics | Study | Universities & Medical Training